Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer?

Man Yu; Ian F Tannock

doi:10.1016/j.ccr.2012.03.002

Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer?

Cancer Cell. 2012 Mar 20;21(3):327-9. doi: 10.1016/j.ccr.2012.03.002.

Authors

Man Yu¹, Ian F Tannock

Affiliation

¹ Ontario Cancer Institute/Princess Margaret Hospital, University Health Network and University of Toronto, Canada.

PMID: 22439929
DOI: 10.1016/j.ccr.2012.03.002

Abstract

Pancreatic ductal adenocarcinoma (PDA) responds poorly to chemotherapy. In this issue of Cancer Cell, Provenzano et al. identify hyaluronan as a pivotal determinant of elevated interstitial fluid pressures (IFP) and vascular collapse in PDA. PEGPH20 treatment ablates stromal hyaluronan, normalizes IFP, and increases accessibility of tumor cells to anticancer drugs.

Publication types

Comment